Germany at a glance
- Population
- 83.5 million 2025
- Life expectancy at birth
- 80.8 years, 2024
- People aged 65 and over
- 23.7 % of people, 2025
- Health spending per person
- 6,849 US$ per person, 2024
- Doctors
- 4.53 per 1,000 people, 2022
Updated
Reviewed by Chandani Patel
Germany Biologics CDMO Market Industry Trends and Forecast to 2034: Segmented by (Product, Service, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$1.20 Bn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $894.3 Mn | — | — |
| 2025 (base) | $977.5 Mn | +$83.2 Mn | — |
| 2026 (forecast) | $1.07 Bn | +$90.9 Mn | +9.3% |
| 2027 (forecast) | $1.17 Bn | +$99.4 Mn | +19.5% |
| 2028 (forecast) | $1.28 Bn | +$108.6 Mn | +30.6% |
| 2029 (forecast) | $1.40 Bn | +$118.7 Mn | +42.7% |
| 2030 (forecast) | $1.52 Bn | +$129.7 Mn | +56% |
| 2031 (forecast) | $1.67 Bn | +$141.8 Mn | +70.5% |
| 2032 (forecast) | $1.82 Bn | +$155.0 Mn | +86.4% |
| 2033 (forecast) | $1.99 Bn | +$169.4 Mn | +103.7% |
| 2034 (forecast) | $2.18 Bn | +$185.2 Mn | +122.6% |
Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
| Market size, 2025 | $977.5 Mn placeholder estimate |
|---|---|
| Forecast, 2034 | $2.18 Bn placeholder estimate |
| Growth (CAGR), 2025–2034 | 9.3% placeholder estimate |
| Years | 2024 historical · 2025 base year · 2026–2034 forecast |
| Also called | Biologics Contract Development and Manufacturing (CDMO) |
| Segments | Product, service and end user (see all) |
| Key players | Lonza Ltd, Samsung Biologics, WuXi Biologics, FUJIFILM Holdings Corporation, Catalent and 1 more (see all) |
| Formats | PDF, PPTX, XLSX |
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
Biologics CDMOs develop and manufacture antibodies, proteins and vaccines for pharma and biotech companies.
Key segments of the biologics CDMO market include product (Monoclonal Antibodies, Recombinant Proteins and Vaccines) and service (Process Development, Clinical Manufacturing and Commercial Manufacturing).
Growing drug pipelines, more complex biologics, cost pressure on drug makers and the need for speed are driving the biologics CDMO market. Many companies now outsource work they used to do in-house.
Advanced therapies, AI-driven operations and expansion in India, China and Southeast Asia give the biologics CDMO market room to grow.
Capacity shortages, strict quality rules, data security concerns and pricing pressure hold back the biologics CDMO market.
The biologics CDMO market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Most people have statutory health insurance; the Federal Joint Committee (G-BA) decides what it covers and rates the added benefit of new medicines.[1]
[1] Federal Joint Committee (G-BA). Checked 14 Nov 2026.
Licensing, quality standards and payment models from public and private payers shape how biologics CDMO services are delivered and paid for in Germany. Government health programs and insurance coverage are key to access.
What doctors and scientists are doing in Biologics CDMO right now, from free public sources.
Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 17 Nov 2026.
[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 18 Nov 2026.
[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 18 Nov 2026.
From our blog
Germany
Germany
Germany
Germany
Germany
Germany
Pharmaceuticals · Germany
Pharmaceuticals · Germany
Pharmaceuticals · Germany
Medical Devices · Germany
Pharmaceuticals · Germany
Pharmaceuticals · Germany